Phase 2 Cardiomyopathy Trial, Recruiting NCT06143566 Sponsor: University of Texas Southwestern Medical Center Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT06143566
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Type 2 diabetes
  • People who have chronic kidney disease at a moderate stage, meaning their kidneys are working at a reduced but not severely low level (confirmed by a specific kidney function measurement called eGFR, falling between 25 and 90), along with a urine test result below a certain threshold for protein leakage
  • People who also have at least one of the following: a high score on a risk assessment tool called the WATCH-DM score (score of 11 or higher), elevated levels of certain heart-stress markers in the blood called natriuretic peptides, or signs of heart muscle changes detected on a heart ultrasound (echocardiogram)

Who may not be able to join:

  • People whose kidney function has declined to a severe level (eGFR below 25)
  • People who have been diagnosed with congestive heart failure
  • People who have high potassium levels in their blood (above 5.0)
  • People who have a medical reason they cannot take any ingredient in the study medication combination (confirm with trial site)
  • People who are pregnant
  • People whose blood creatinine level (a measure of kidney waste) is above a certain level — over 2.0 mg/dL for men or over 1.8 mg/dL for women
  • People for whom the WATCH-DM risk score cannot be calculated
  • People who are unable to undergo exercise testing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ambarish Pandey, MD, MSCS, UT Southwestern

Phone: 214-645-2101

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
11 March 2024
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Oxygen uptake during peak exercise (Peak VO2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov